A recently developed nanotechnology, the Integral Molecular lipoparticle, provides an essentially soluble cell-free system in which G-protein-coupled receptors (GPCRs) in their native conformations are concentrated within virus-like particles. As a result, the lipoparticle provides a means to overcome 2 common obstacles to the development of homogeneous, nonradioactive GPCR ligand-binding assays: membrane protein solubilization and low receptor density. The work reported here describes the first application of this nanotechnology to a fluorescence polarization (FP) molecular binding assay format. The GPCR chosen for these studies was the well-studied chemokine receptor CXCR4 for which a peptide ligand (T-22) has been previously characterized. The EC 50 determined for the CXCR4-T-22 peptide interaction via FP with CXCR4 lipoparticles (15 nM) is consistent with the IC 50 determined for the unlabeled T-22 peptide via competitive binding (59 nM). (Journal of Biomolecular Screening 2008:424-429) 
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRs) mediate a wide range of cell adhesion events and intracellular signaling and regulatory pathways. 1 They are, therefore, drug targets that are of particular interest to the pharmaceutical industry. A subclass of membrane proteins, GPCRs are challenging to target because they are often very difficult to purify away from cells in their native conformation and are usually unstable in solubilized formats. Because they are difficult to extract from the cell membrane in a stable form that maintains their native conformation, the number of techniques that can be used to study ligand-GPCR interactions is limited. The scintillation proximity assay (SPA) is a popular, homogeneous (wash-free) assay, but the expense and safety issues inherent to this radioactive assay format present several significant drawbacks, including safety, waste disposal, and cost. 2 Nonradioactive methods using whole cells, cell membrane-derived preps, or vesicles are options that sometimes circumvent these issues, 1, 3 but sufficient levels of expression required for such assays often cannot be achieved. As a result, the development of nonradioactive, homogeneous GPCR molecular binding assays has proven to be problematic.
Integral Molecular's lipoparticle technology overcomes many of these challenges by presenting concentrated membrane proteins in a cell-free lipid environment. 4, 5 The lipoparticle is a nanometerscale vehicle that allows for the presentation and manipulation of enriched, conformationally intact membrane proteins. It consists of a 100-to 200-nm virus-like particle surrounded by a lipid bilayer derived directly from the cell surface and carrying the membrane proteins from that surface. Lipoparticles are produced by first inducing cells to express high levels of the membrane protein of interest and a retroviral Gag core protein at the same time. 6 This results in capturing the overexpressed host cell membrane proteins on the surface of budded retroviral-like particles (also referred to as "pseudotypes"). The enrichment of the desired protein is optimized by harvesting the lipoparticles at the peak of protein expression.
It has been known for some time that foreign membrane proteins can be incorporated onto the surface of budding retroviruses. Such foreign proteins were first thought to be limited to other viral Envelope proteins, but cellular membrane proteins, such as CD4, were also discovered to be incorporated. 7 Some membrane proteins may be excluded from retroviral incorporation, possibly due to exclusion from lipid rafts (the point of assembly for many retroviruses), 8 but definitive inclusion or exclusion rules have not yet been defined. 9 The successful incorporation of complex membrane proteins, such as GPCRs and 14-transmembrane transporters, [4] [5] [6] suggests that a diverse assortment of proteins can be incorporated into retroviruses if expressed at sufficient levels on the cell surface. Because the lipoparticle purifies the membrane protein away from the cell, it offers an enriched source of membrane protein in an essentially soluble format. Membrane proteins of interest within lipoparticles are typically enriched 10-to 100-fold compared with cells or membrane preps (measuring specific membrane protein per total protein concentrations; unpublished data). Enrichment is likely not due to selective receptor uptake into viral particles but rather because contaminating cytosolic proteins, irrelevant membrane structures, and inverted membrane proteins are not included in lipoparticle preparations. Lipoparticle technology, therefore, presents a novel solution to a primary obstacle-the enrichment of conformationally intact GPCRs-encountered when developing GPCR-ligand molecular assays.
Lipoparticle technology is being used within several areas of drug discovery, including monoclonal antibody development, high-throughput screening (HTS), and membrane protein crystallography. Lipoparticles have also been used previously to study membrane protein-ligand interactions. 6 Successful immobilization of CXCR4-containing lipoparticles to a biosensor surface enabled the determination of the equilibrium dissociation constants for the interaction with both HIV-1 gp120 and an anti-CXCR4 antibody. Although this work highlights the potential for lipoparticle technology to probe biomolecular interactions, biosensor instrumentation is not currently available in an ultra-HTS (uHTS) format.
Fluorescence polarization (FP) has become a critical technology for uHTS assays. Its application to GPCR-ligand interactions has been limited by a number of factors, including insufficient receptor density, receptor solubilization, and nonspecific binding of fluorescently labeled ligand. Previously suggested requirements for a successful FP uHTS GPCR assay include a minimum expression level of 1 pmol/mg, ligandbinding affinity of at least 10 nM, and a fluorophore with sufficient quantum yield to allow for experiments to be run at 1 nM ligand or less. 10 Lee and Bevis 3 reported that attempts at developing an FP GPCR ligand-binding assay with 0.6 pmol receptor/mg protein were unsuccessful due to poor FP signal. Lower expression levels cannot be readily overcome by increasing the amount of membrane preps in these reaction mixtures due to the significant contribution of membranes to light scattering. These requirements have been challenging to meet with the standard sources of GPCRs. For example, the propensity of cells and membrane preps to settle in solution within the time frame of a binding assay increases the difficulty in developing this type of uHTS FP assay. Because lipoparticles typically exceed the minimum expression level recommended for FP assays, and because there is a significant molecular weight and volume difference between lipoparticles and potential GPCR ligands, we decided to test the feasibility of using this nanotechnology in a fluorescence polarization GPCR ligand-binding assay format.
CXCR4 was chosen as a model receptor to test the feasibility of using lipoparticles in an FP assay for several reasons. First, as noted above, CXCR4 lipoparticles have been used successfully to measure CXCR4-ligand interactions on a biosensor. Second, CXCR4 lipoparticles have been well characterized in developing the lipoparticle technology. Third, a small peptide ligand (T-22) has been previously identified with a low nanomolar IC 50 for CXCR4, 11 which is suitable for FP. T-22 is an 18-amino acid peptide derived from tachyplesin and polyphemusin, self-defense peptides of horseshoe crabs. It has been shown to specifically inhibit T-tropic HIV-1 infections by interfering with membrane fusion mediated by CXCR4. 12 T-22 inhibits calcium mobilization and chemotaxis induced by the CXCR4 ligand SDF-1α and has been shown to inhibit the binding of SDF-1α to CXCR4. 12, 13 The IC 50 of T-22 for CXCR4 has been reported to range from 48 to 71 nM. 11 A second peptide, 4Ala-T-I, has also been characterized previously and shown to be a well-matched negative control for T-22. 12 This peptide is 17 amino acids in length, can be readily fluorescently labeled, and is similar to T-22 in its hydrophobic and basic properties. T-22 thus offers a well-described system for adaptation to FP. Together, T-22 and the CXCR4 lipoparticle potentially overcome the challenges presented by GPCRs using traditional FP assays: receptor concentration, receptor solubility, and availability of a fluorescently labeled ligand of suitable affinity. 3, 10 
MATERIALS AND METHODS

Lipoparticles and peptides
CXCR4 lipoparticles were produced at Integral Molecular (Philadelphia, PA) as previously described 6 by transfecting HEK-293T cells with a 3:1 ratio of receptor plasmid to pCGP, the latter of which encodes the Murine leukemia virus (MLV) gag and pol genes. Supernatant was clarified by 0.45-mm filtration and then pelleted through sequential 20% sucrose cushions by ultracentrifugation in an SW28 rotor. The lipoparticles were resuspended in 10 mM HEPES (pH 7), 0.01% sodium azide, and 0.5% sucrose and were stored in this solution at 4 °C until the day of use. The total protein concentration was reported to be 0.2 mg/mL, and the CXCR4 concentration was estimated to be approximately 5% of the total protein concentration by Sypro staining.
Both fluorescently labeled and unlabeled T-22 and 4Ala-T-I (control) peptides were purchased from AnaSpec, Inc. (San Jose, CA). The sequences of both peptides were as described in Murakami et al. 12 The fluorophore Oregon Green 488 was linked to both peptides through a 6-carbon linker to the N-terminus of both labeled peptides. Oregon Green was used due to its fluorescence lifetime, quantum yield, and excitation and emission wavelengths. The molecular weight and purity of both peptides were analyzed by high-performance liquid chromatography (HPLC) and mass spectrometry by AnaSpec. Further mass spectrometry work was performed to confirm that both T-22 disulfide bridges were formed. The lyophilized peptides were dissolved in 20 mM HEPES, 100 mM NaCl (pH 7.2), at a concentration of 0.4 mg/mL on the day of use.
FP assay
The absorbance spectra of both the labeled T-22 and labeled control peptide (4 Ala-T-I) were obtained on a Lambda 40 UV/Vis spectrometer (PerkinElmer, Wellesley, MA) in assay buffer (20 mM HEPES, 100 mM NaCl, 2 mM MgCl 2 , 2 mM CaCl 2 , pH 7.2) to guide the choice of excitation wavelength for fluorescence experiments, as well as to avoid inner filter effect artifacts. The absorbance maximum of both peptides was 498 nm. The excitation and emission spectra were obtained for both labeled peptides to guide the choice of excitation and emission filters for FP measurements. The emission and excitation spectra of both peptides were obtained on a SLM Aminco Model 8100 spectrofluorometer (HORIBA Jobin Yvon, Stanmore, London, UK) at room temperature with excitation slits set at 2,2; emission slits set at 8,8; and polarizers set to the magic angle. The excitation and emission maxima of both fluorescently labeled peptides were 500 nm and 523 nm, respectively. FP binding titrations were performed in assay buffer in 96-well half-area, flat-bottom, nonbinding surface plates (Corning Incorporated Life Sciences, Acton, MA) in 75-μL reaction volumes. The concentrations of labeled peptides were chosen so that the intensity of the fluorophore was more than an order of magnitude greater than the background intensity. Direct binding titrations involved the addition of CXCR4-containing lipoparticles to 20 nM labeled T-22. Due to lower fluorescence intensity, titrations in which CXCR4-containing lipoparticles were added to labeled control peptide included 40 nM of the labeled control peptide. For comparison purposes, direct binding titrations were performed with 40 nM labeled T-22. After mixing the 2 reactants, solutions were allowed to incubate for 90 min at room temperature prior to measurement of fluorescence polarization on an LJL BioSystems Analyst AD System 96/384 Well Plate Reader (Molecular Devices, Sunnyvale, CA). The excitation filter used was fluorescein/ Oregon Green 485 nm-20, the emission filter used was fluorescein/ Oregon Green 530 nm-25, and a FL-505 beam splitter was used. The EC 50 was determined for the CXCR4-T-22 interaction with nonlinear least squares regression analysis.
Competitive binding experiments involved titrating either unlabeled T-22 or control peptides into a constant concentration of the CXCR4 lipoparticle/probe (labeled T-22 or control peptide) complex. The competitor was typically titrated into a CXCR4/ probe complex at concentrations ranging from 2 μM to 1 nM, and the reactants were allowed to incubate for 90 min at room temperature before the fluorescence polarization was measured as described above. These data were fit to derive an IC 50 value with nonlinear least squares regression analysis.
Microscopy
To confirm peptide binding to particles with receptors, we diluted labeled or unlabeled peptides to 100 or 400 nM with 10 mM HEPES, 100 mM NaCl, pH 7.4. Lipoparticles produced with CXCR4 or with no specific receptor were then added to a final concentration of 50 μg/mL. This solution was incubated for 10 min at room temperature, mixed with a 5-fold excess of buffer to dilute unbound peptide, transferred to a glass slide with a coverslip, and incubated an additional 5 min to allow lipoparticles to adhere to the glass.
RESULTS AND DISCUSSION
T-22 direct binding to CXCR4 lipoparticle
Upon binding to CXCR4 lipoparticles, the fluorescence polarization of the labeled T-22 peptide increased from an average of 112 mP to 419 mP. This large signal window is most likely related to the size of the lipoparticle, which was determined by electron microscopy and dynamic light scattering to be between approximately 150 and 200 nm (data not shown). The physical size of the lipoparticles suggests that small protein ligands, or possibly even antibodies, could be used in an FP assay format.
The data presented here show that the receptor density of CXCR4 is sufficient to provide a robust signal with a minimal amount of scattered light. Because the reported percentage of CXCR4 content in the lipoparticles is an approximation (5%), the concentrations of CXCR4 shown in Figure 1 are also approximations. The data were therefore analyzed for an EC 50 rather than for an equilibrium dissociation constant (Fig. 1) . The EC 50 determined by this fit is low nanomolar (15 nM), consistent with the IC 50 s determined for this interaction by measuring the inhibitory effect of T-22 on the binding of a monoclonal antibody (12G5) to CXCR4 via flow cytometry (48 nM, 71 nM). 11
Binding specificity
The specificity of the binding interaction between T-22 and the CXCR4 lipoparticle was probed using a labeled control peptide (4-Ala-T-I). As previously reported, the control peptide was matched to the hydrophobicity and basic properties of T-22 and was previously shown by Murakami et al. 12 to serve as an appropriate T-22 negative control in a variety of cellular readouts, including SDF-1α-induced Ca 2+ mobilization. As shown in Figure 2 , addition of CXCR4 lipoparticles to the control peptide did not result in any increase of the FP signal, whereas addition of the same concentration of the CXCR4 lipoparticle to the labeled T-22 peptide resulted in an FP increase of approximately 86 mP.
Competitive binding assays were performed to further probe the specificity of the T-22-CXCR4 interaction. Unlabeled control peptide was added to the labeled T-22/CXCR4 complex up to 1 μM with no resultant decrease in the FP signal (Fig. 3A) , as expected. In contrast, addition of unlabeled T-22 peptide to the labeled T-22/CXCR4 complex did cause a dose-dependent decrease in the FP signal (Fig. 3B) . In fact, the FP signal decrease approached that of the free peptide mP values with addition of 250 nM unlabeled T-22 peptide. The observed low level of nonspecific binding enables the direct use of the FP raw data without any additional corrections, as has been necessary in other systems. 3 The IC 50 derived from these data (59 nM) is in good agreement with the IC 50 s determined by Tamamura et al. 11 (48 nM and 71 nM) as well as with the EC 50 determined for the labeled T-22 peptide-CXCR4 lipoparticle interaction (15 nM) ( Fig. 1) .
Confirmation of T-22 binding and lipoparticle integrity
To confirm the FP results, we used the fluorescence of the Oregon Green probe linked to the T-22 peptide to directly visualize the binding of the peptide to CXCR4 lipoparticles via fluorescent microscopy. A similar method, fluorescence fluctuation spectroscopy, has previously been used to visualize fluorescent ligand binding to virus-like particles containing GPCRs. 14 Addition of 100 nM and 400 nM labeled T-22 peptide to otherwise unlabeled CXCR4-lipoparticles could clearly be visualized by fluorescent microscopy, suggesting that the peptide is binding to CXCR4 on the lipoparticles (Fig. 4) . As a control for specificity, we tested lipoparticles lacking CXCR4, which did not result in any detectable binding of labeled T-22, as predicted. Fluorescently labeled control peptide, at a concentration of 400 nM, also failed to bind to CXCR4 lipoparticles, as expected (data not shown).
An additional concern, presented with the use of nonendogenous receptors in an artificially manipulated system, is the potential for structural modifications that affect the receptor's ligand-binding properties due to integration into the lipoparticle environment. We have addressed these concerns by demonstrating that CXCR4 within lipoparticles is capable of binding numerous conformation-dependent antibodies, 15 as well as HIV-1 Envelope 5,15 and its cognate chemokine SDF-1α (data not shown). Incorporation of additional GPCRs, such as endothelin A, into virus-like particles by an independent group has confirmed that the ligand-binding affinity of endothelin-1 to the GPCR within viruslike particles and traditional membrane fragments is essentially identical. 14 The work shown here is the first time that FP has successfully been used to monitor a GPCR-ligand interaction with lipoparticle technology. With the appropriate controls to monitor for disruption of the lipid bilayer, this work demonstrates that lipoparticle nanotechnology can successfully overcome several of the major challenges to the measurement of GPCR-ligand interactions. Many applications in which lipoparticles have been successfully used, including Biacore biosensor, FP, and GTP-gamma-S binding assays (unpublished), are known to work poorly or not at all with traditional membrane preps.
More than a dozen different GPCRs have been incorporated into lipoparticles, so the results here are expected to be applicable to any other GPCR. Further validation work, including the analysis of a test library of compounds and the assessment of the suitability of using this assay to search for novel antagonists, is necessary prior to assessing the feasibility of applying this FP assay to an uHTS format. 
